Abstract
Trandolapril is the pro-drug of trandolaprilat, a non-sulfhydryl angiotensin-converting enzyme inhibitor. This study was designed to assess the pharmacokinetics (PK), pharmacodynamics (PD), and tolerability of single and multiple doses of trandolapril in healthy Chinese subjects. Healthy subjects (six men and six women) were randomized into a single-dose, 3 × 3 crossover study (1–2–4 mg, 2–4–1 mg, and 4–1–2 mg), and a multiple-dose study (2 mg/day, 6 days). Serial blood and urine samples were collected after drug administration and analyzed using a validated LC–MS/MS method, and the trandolapril and trandolaprilat PK parameters were obtained. PD was evaluated by the changes in blood pressure and heart rates after dosing. Tolerability was assessed by monitoring adverse events, vital signs, ECGs, and changes in laboratory tests. In the single-dose study, trandolapril was absorbed rapidly, and peak plasma levels (C max, 1.57, 3.77, and 7.99 ng/mL) and AUCs (1.89, 3.46, and 6.47 ng/mL) were dose-dependent. The AUC0–∞ of trandolaprilat was dose-dependent, but in a non-linear fashion. The cumulative urine excretion of trandolapril and trandolaprilat was 5.51, 6.20, and 7.41 % for three doses, respectively. In the multiple-dose study, steady-state pharmacokinetics was observed; there was no trandolapril accumulation, but there was mild trandolaprilat accumulation (R = 1.67). Trandolapril was well tolerated. The most pronounced reductions in blood pressure were observed at 8 h after administration, which was later than T max. No orthostatic hypotension occurred. The pharmacokinetics and pharmacodynamics following single and multiple oral doses trandolapril in healthy Chinese subjects are similar to those observed in non-Chinese healthy subjects.
Similar content being viewed by others
References
Guay DR. Trandolapril: a newer angiotensin-converting enzyme inhibitor. Clin Ther. 2003;25:713–75.
Wiseman LR, McTavish D. Trandolapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs. 1994;48:71–90.
Zannad F. Trandolapril. How does it differ from other angiotensin converting enzyme inhibitors? Drugs. 1993;46(Suppl 2):172–81.
Duc LN, Brunner HR. Trandolapril in hypertension: overview of a new angiotensin-converting enzyme inhibitor. Am J Cardiol. 1992;70:27D–34D.
Conen H, Brunner HR. Pharmacologic profile of trandolapril, a new angiotensin-converting enzyme inhibitor. Am Heart J. 1993;125:1525–31.
de Leeuw PW. Trandolapril: a clinical profile. Am J Hypertens. 1995;8:68S–70S.
Danielson B, Querin S, LaRochelle P, Sultan E, Mouren M, Bryce T, Stepniewski JP, Lenfant B. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to patients with chronic renal failure and healthy control subjects. J Cardiovasc Pharmacol. 1994;23(Suppl 4):S50–9.
Lenfant B, Mouren M, Bryce T, De Lauture D, Strauch G. Trandolapril: pharmacokinetics of single oral doses in healthy male volunteers. J Cardiovasc Pharmacol. 1994;23(4):S38–43.
MAVIK® (Trandolapril Tablets) Description. NDC Code(s): 0074-2278-13, 0074-2279-13, 0074-2280-13, Packager: AbbVie Inc.
De Ponti F, Marelli C, D’Angelo L, Caravaggi M, Bianco L, Lecchini S, Frigo GM, Crema A. Pharmacological activity and safety of trandolapril (RU 44570) in healthy volunteers. Eur J Clin Pharmacol. 1991;40:149–53.
Patat A, Surjus A, Le Go A, Granier J. Safety and tolerance of single oral doses of trandolapril (RU 44.570), a new angiotensin converting enzyme inhibitor. Eur J Clin Pharmacol. 1989;36:17–23.
Arner P, Wade A, Engfeldt P, Mouren M, Stepniewski JP, Sultan E, Bryce T, Lenfant B. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to young and elderly patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol. 1994;23(Suppl 4):S44–9.
Pistosa C, Koutsopouloua M, Panderib I. Liquid chromatographic tandem mass spectrometric determination of trandolapril in human plasma. Anal Chim Acta. 2005;540:375–82.
Nirogi RV, Kandikere VN, Shrivastava W, Mudigonda K. Quantification of trandolapril and its metabolite trandolaprilat in human plasma by liquid chromatography/tandem mass spectrometry using solid-phase extraction. Rapid Commun Mass Spectrom. 2006;20:3709–16.
Tytus RH, Burgess ED, Assouline L, Vanjaka A. A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL). Clin Ther. 2007;29:305–15.
Weber S, Vaur L, Ounnoughene Z, Schwob J, Dubroca I, Normand J, Etienne S, Charbonnier B. Acute blood pressure response to trandolapril and captopril in patients with left ventricular dysfunction after acute myocardial infarction. Am Heart J. 2002;143:313–8.
Acknowledgments
This work was financially supported by National Major Scientific and Technological Special Project for “Significant New Drugs Development” during the Twelfth Five-Year Planning Period of China (Project: 2014ZX09303303) and the National Natural Science Foundation of China (Project: 81430087).
Conflict of interest
The authors have indicated that they have no other conflicts of interest regarding the content of this article.
Author information
Authors and Affiliations
Corresponding author
Additional information
Xiaojiao Li and Chang Liu have contributed equally to this work.
Rights and permissions
About this article
Cite this article
Li, X., Liu, C., Wu, M. et al. Pharmacokinetics, Pharmacodynamics, and Tolerability of Single and Multiple Doses of Trandolapril, an Effective Angiotensin-Converting Enzyme Inhibitor, in Healthy Chinese Subjects. Eur J Drug Metab Pharmacokinet 41, 373–384 (2016). https://doi.org/10.1007/s13318-015-0277-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13318-015-0277-2